Lexicon Pharmaceuticals Inc - LXRX STOCK NEWS

Lexicon Pharmaceuticals (Nasdaq: LXRX) supports the European Society of Cardiology's updated guidelines recommending SGLT inhibitors for heart failure treatment. This recommendation emphasizes the drugs' Class IA endorsement for reducing cardiovascular death and hospitalization risks in patients, especially those with diabetes. Notably, sotagliflozin, an investigational drug, was highlighted for its potential benefits before regulatory approval. Lexicon plans to file a New Drug Application with the FDA later this year for sotagliflozin as a heart failure therapy.

Lexicon Pharmaceuticals (LXRX) announced findings from the SOLOIST and SCORED trials for sotagliflozin at ESC Congress 2021. The trials revealed a 33% absolute reduction in cardiovascular risks for type 2 diabetes patients with acute heart failure and a 26% reduction in those with chronic kidney disease. Notably, the 400 mg dosage showed significant benefits in reducing heart failure events. The company plans to submit a New Drug Application for sotagliflozin, highlighting its potential as a treatment for heart failure in diabetes patients.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has appointed Craig Granowitz, M.D., Ph.D., as the new senior vice president and chief medical officer, effective August 2, 2021. Granowitz brings extensive pharmaceutical experience, previously serving as CMO at Amarin Corporation and holding senior roles at Merck & Co. He is expected to lead the medical affairs organization and oversee the development of Lexicon's drug pipeline, particularly sotagliflozin, aimed at treating heart failure in type 2 diabetes patients. He possesses a strong background in cardiovascular medicine, crucial for advancing Lexicon's therapeutic goals.

Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q2 2021 financial results, revealing a significant revenue drop to $0.2 million from $9.2 million in Q2 2020, primarily due to the cessation of product sales after the XERMELO divestiture. R&D expenses decreased to $10.3 million, while SG&A expenses fell to $7.9 million. The net loss improved to $18.1 million ($0.13 per share) compared to the prior year's loss of $69.1 million ($0.65 per share). The company anticipates filing a New Drug Application for sotagliflozin by year-end and reports increased enrollment in ongoing Phase 2 studies of LX9211.

Lexicon Pharmaceuticals (Nasdaq: LXRX) will announce its second-quarter 2021 financial results on July 30, 2021, before market opening. A conference call is scheduled at 8:00 a.m. ET to discuss these results and provide a business update. The company is advancing drug candidates through its Genome5000™ program, which targets over 100 proteins for various diseases. Lexicon has one drug on the market and a pipeline focused on neuropathic pain, heart failure, and diabetes. For more details, visit lexpharma.com.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced a symposium on sotagliflozin during the American Diabetes Association’s 81st Scientific Sessions from June 25-29, 2021. The event will focus on updates from the SCORED and SOLOIST cardiovascular and kidney outcomes trials on June 29. Sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, is approved in the EU for adults with type 1 diabetes who struggle with glycemic control despite optimal insulin therapy, yet has not been commercially launched. This highlights Lexicon's commitment to advancing diabetes treatment.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that CEO Lonnel Coats will present at the 2021 Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:30 a.m. ET. A live webcast of the presentation will be accessible on Lexicon's website, with an archived version available for two weeks post-event.

Lexicon focuses on pioneering innovative medicines through its Genome5000™ program, having identified over 100 protein targets for various diseases. The company's portfolio includes drug candidates in clinical and preclinical development for conditions like neuropathic pain and diabetes.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced two virtual presentations on sotagliflozin at the American College of Cardiology’s 70th Annual Scientific Session from May 15-17, 2021.

The first presentation, on May 16, will discuss the SOLOIST-WHF trial findings, highlighting how sotagliflozin reduces hospitalizations and increases patient days outside the hospital. The second presentation, on May 17, will focus on the benefits of sotagliflozin across various heart failure conditions.

Lexicon Pharmaceuticals (LXRX) reported its Q1 2021 financial results, revealing negligible revenues due to the previous sale of XERMELO. The net loss narrowed to $21 million, or $0.15 per share, compared to $66.6 million, or $0.63 per share, in Q1 2020. Research and Development (R&D) expenses decreased significantly to $12.6 million from $55.2 million, as clinical studies concluded. Lexicon continues to enroll patients in two Phase 2 studies for LX9211 targeting neuropathic pain and received positive FDA feedback for sotagliflozin, with plans for an NDA filing this year.